Intravenous Stem Cell Therapy in Cardiovascular Diseases: Physiopathologie, Mécanismes biochimiques, and Therapeutic Potential

Abstrait

Maladies cardiovasculaires (CVD) restent la première cause de mortalité dans le monde. Despite major advancements in pharmacological and surgical treatments, myocardial tissue regeneration remains a significant challenge. Stem cell-based therapy, particularly intravenous (IV) stem cell administration, has emerged as a promising modality to repair, régénérer, and restore cardiac function. This article explores the pathophysiology of various cardiac diseases, the biochemical and molecular mechanisms underlying stem cell therapy, and evaluates the efficacy of IV stem cell injections in treating these conditions. Emphasis is placed on ischemic heart disease, infarctus du myocarde, et insuffisance cardiaque, which represent the most extensively studied cardiovascular indications for stem cell treatment.

---

Introduction

Le coeur, once thought to be a post-mitotic organ with limited regenerative capacity, is now understood to possess some degree of plasticity. Néanmoins, in the event of significant injury, comme l'infarctus du myocarde, the endogenous repair mechanisms are insufficient. Traditional therapies can manage symptoms and prolong life but fail to regenerate necrotic myocardium. Stem cell therapy seeks to overcome this limitation. Various routes of administration have been explored, with IV injection being one of the least invasive and most feasible options. This review provides a comprehensive analysis of how stem cells work at the biochemical and molecular level to combat cardiac pathology and restore function.

---

Pathophysiology of Cardiovascular Diseases

1. Ischemic Heart Disease and Myocardial Infarction

Ischemic heart disease results from an imbalance between myocardial oxygen supply and demand, often due to atherosclerotic coronary artery disease. Atherosclerosis leads to plaque formation and narrowing of coronary vessels. When a plaque ruptures, it can occlude the vessel, causing myocardial infarction (MI).

Voies biochimiques:

• Ischemia-induced oxidative stress leads to excessive production of reactive oxygen species (ROS).
• Calcium overload due to mitochondrial dysfunction.
• Activation of apoptotic and necrotic pathways through p53, Bax, and caspase cascades.
• Inflammatory signaling via NF-κB, TNF-α, IL-1β, and IL-6.

2. Insuffisance cardiaque chronique

Insuffisance cardiaque (HF) is characterized by the heart’s inability to pump sufficient blood to meet the body’s needs. It typically follows an MI or chronic hypertension.

Voies biochimiques:

• Neurohormonal activation, especially of the renin-angiotensin-aldosterone system (RAAS).
• Elevated natriuretic peptides (BNP, ANP) as compensatory mechanisms.
• Increased oxidative stress et dysfonctionnement mitochondrial.
• Matrix metalloproteinases (MMP) activation leading to extracellular matrix remodeling.

---

Cellules souches: Types and Mechanisms

Types of Stem Cells Used in Cardiology

1. Cellules souches mésenchymateuses (MSC): Dérivé de la moelle osseuse, tissu adipeux, cordon ombilical. Known for immunomodulatory and paracrine effects.
2. Cellules souches pluripotentes induites (iPSC): Generated from adult somatic cells, reprogrammed to a pluripotent state.
3. Cellules souches cardiaques (CSC): Native to the myocardium, capable of differentiating into cardiac lineages.
4. Cellules progénitrices endothéliales (CPE): Contribute to angiogenesis and endothelial repair.

Mécanismes d'action

• Signalisation paracrine: Release of growth factors (VEGF, IGF-1, HGF, SDF-1) that stimulate repair.
• Immunomodulation: MSCs suppress pro-inflammatory cytokines and promote regulatory T cell activity.
• Angiogenèse: Promoting neovascularization to improve perfusion.
• Anti-apoptotic effects: Reduction in caspase activity and improved mitochondrial integrity.
• Différenciation: Limited evidence suggests potential for integration into myocardium and differentiation into cardiomyocytes.

---

Intravenous Delivery of Stem Cells

Avantages

• Peu invasif.
• Easier to perform repeatedly.
• Potential for systemic effects, including remote ischemic zones.

Disadvantages

• Pulmonary first-pass effect: A significant proportion of cells are trapped in the lungs.
• Homogeneity and cell survival issues: Reduced targeting to myocardium.

Strategies to Enhance IV Efficacy

• Preconditioning of cells with hypoxia or pharmacologic agents.
• Genetic modification to overexpress chemokine receptors like CXCR4 to enhance homing.
• Use of nanoparticles or scaffolds to increase retention and viability.

---

Clinical Applications and Evidence

1. Infarctus du myocarde

Numerous clinical trials (PAR EX., BOOST, REPAIR-AMI) have demonstrated improved left ventricular ejection fraction (FEVG) and reduced infarct size after IV administration of bone marrow-derived stem cells.

2. Chronic Ischemic Heart Disease

Studies using MSCs have shown improvements in exercise tolerance and angina frequency, attributed to enhanced myocardial perfusion via angiogenesis.

3. Insuffisance cardiaque congestive

MSC therapy has shown promise in reducing hospitalizations, improving NYHA functional class, and enhancing quality of life. Paracrine effects are believed to reduce fibrosis and promote cardiomyocyte survival.

---

Biochemical and Molecular Insights

Stem cell therapy affects several molecular pathways:

• PI3K/Akt and ERK1/2 pathways: Promote cell survival and proliferation.
• Axe SDF-1/CXCR4: Critical for stem cell homing.
• HIF-1α stabilization: Enhances angiogenesis in hypoxic tissue.
• TGF-β modulation: Reduces pathological remodeling.
• miRNA expression: miR-21, miR-126, and others modulated by stem cell therapy contribute to anti-apoptotic and pro-angiogenic effects.